| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 68001-0487-06 | 68001-0487 | CAPECITABINE | CAPECITABINE | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb 22, 2021 | In Use | |
| 00310-4513-60 | 00310-4513 | Acalabrutinib | CALQUENCE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Feb 19, 2025 | In Use | |
| 00703-5043-01 | 00703-5043 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sep 1, 1995 | Mar 31, 2019 | No Longer Used |
| 00703-4246-01 | 00703-4246 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 1, 2006 | In Use | |
| 70121-1238-01 | 70121-1238 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | May 31, 2018 | In Use | |
| 00069-0135-01 | 00069-0135 | Bosutinib monohydrate, Bosutinib | Bosulif | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 4, 2012 | In Use | |
| 42737-0104-14 | 42737-0104 | temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec 31, 2018 | Jan 24, 2019 | In Use |
| 54868-5474-00 | 54868-5474 | Erlotinib Hydrochloride | Tarceva | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 21, 2005 | In Use | |
| 66758-0047-02 | 66758-0047 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 31, 2010 | Jul 15, 2015 | In Use |
| 00078-0594-61 | 00078-0594 | Everolimus | Afinitor | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jul 9, 2010 | In Use | |
| 00002-5337-54 | 00002-5337 | Abemaciclib | Verzenio | 150.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct 6, 2017 | In Use | |
| 47335-0893-87 | 47335-0893 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
| 25021-0255-05 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 1, 2024 | In Use | |
| 31722-0365-31 | 31722-0365 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Oct 15, 2024 | In Use | |
| 40051-0608-13 | 40051-0608 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
| 75907-0169-11 | 75907-0169 | Fluorouracil Cream, 0.5% | FLUOROURACIL | 5.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Jul 6, 2025 | In Use | |
| 69784-0620-25 | 69784-0620 | Busulfan | MYLERAN | 2.0 mg/1 | Chemotherapy | Alkylating Agent | Alkylsulfonate | Oral | Jun 30, 2022 | In Use | |
| 00093-7639-41 | 00093-7639 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | Jul 31, 2019 | In Use |
| 43598-0458-36 | 43598-0458 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF | Oral | Jun 8, 2022 | In Use | |
| 67457-0486-99 | 67457-0486 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | Mar 30, 2012 | Apr 30, 2016 | No Longer Used |
| 63323-0117-58 | 63323-0117 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 12, 2000 | In Use | |
| 42292-0053-05 | 42292-0053 | Erlotinib hydrochloride | Erlotinib Hydrochloride | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 28, 2019 | Jan 31, 2021 | No Longer Used |
| 69945-0452-04 | 69945-0452 | sodium iodide i 131 | SODIUM IODIDE I 131 | 1.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct 27, 2015 | Jul 1, 2018 | No Longer Used |
| 20536-0322-01 | 20536-0322 | Vincristine Sulfate | Marqibo | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Jan 14, 2013 | Oct 26, 2020 | In Use | ||
| 00003-0855-22 | 00003-0855 | Dasatinib | Sprycel | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 28, 2010 | In Use |
Found 11888 results — Export these results
Home